Pharmatek adds further cGMP spray drying capacity to meet demand for improved pharmaceutical solubility

Company has also installed a high pressure, precision roller compactor to further support the development of spray-dried dispersions.

Catalent acquired Pharmatek Laboratories in September 2016, to add extensive early-phase drug development capabilities from preclinical to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds.

“This is the first of several strategic investments that we have planned for the San Diego facility in the immediate future,” commented Barry Littlejohns, President of Catalent’s Drug Delivery Solutions business. He added: “Last year’s acquisition of Pharmatek, and its spray drying capabilities, enables us to provide customers with a comprehensive suite of solubility and bioavailability enhancement solutions, while complementing and expanding Catalent’s OptiForm Solution Suite platform, our science-driven parallel screening approach to identify for customers the optimal formulation pathway for poorly soluble compounds.”